SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK Crypto is trending as its highly engaged community rallies behind its unique narrative to challenge traditional retirement systems. Recent excitement is driven by its appearance in a major exchange's presentation and upcoming marketing campaigns, with many holders showcasing strong conviction through staking and a shared belief in its long-term potential.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid intense media M&A drama, as Paramount Skydance escalates its hostile bid for Warner Bros. Discovery, directly challenging Netflix's reported offer and raising concerns about potential regulatory hurdles. The ongoing uncertainty and perceived market "manipulation" are frustrating many investors, who are torn between fears of increased debt and the belief that the stock is "too cheap to ignore" ahead of its imminent earnings report.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active community passionately championing the "OG meme" narrative of Rage Comics, positioning it as the foundational "meme reset" for an upcoming market cycle. This dedicated base is consistently building out an ecosystem with tools like RageMaker and RageGames, expressing strong conviction for significant long-term growth and leadership in the meme coin space, and urging others to "Return to the Memes" and "Rage On."

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is actively discussed amidst its presence at a major healthcare conference, highlighted by the strategic appointment of a Chief Commercial Officer and completed enrollment in a key obesity maintenance study for VK2735. The community is eagerly anticipating regulatory clarity for its oral VK2735 to advance directly to Phase 3, alongside pervasive speculation around potential partnerships or a lucrative buyout. This excitement stems from the drug's perceived best-in-class profile and strong differentiation in the rapidly expanding GLP-1/GIP agonist market.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending due to significant market volatility surrounding its FILSPARI sNDA for FSGS, following an FDA request for additional clinical benefit data. While some anticipate a Complete Response Letter and further declines, many investors view the sharp sell-off as an exaggerated reaction, highlighting strong existing product sales and cash reserves as a buying opportunity. The immediate focus is on the regulatory outcome for this label expansion, which contrasts with the drug's robust performance in its IgAN indication.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as community discussions center on recent statements regarding big tech's responsibility for data center electricity costs, fueling debate around future AI infrastructure investments. While some view current price action as underperforming, others see it as an accumulation opportunity ahead of upcoming earnings amid the broader context of intense AI competition and power demand for cloud services.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending due to its escalating hostile takeover bid for Warner Bros. Discovery (WBD), having reiterated its all-cash offer and initiated a lawsuit seeking financial disclosures from WBD. The community is actively debating the superior value of PSKY's bid over Netflix's alternative, with much discussion centered on WBD's board resistance and the broader implications for media industry consolidation and regulatory hurdles.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following cautious 2026/2027 revenue guidance, largely driven by the anticipated impact of DefenCath's reimbursement shift in mid-2026, which triggered a sharp sell-off. The community is deeply divided, with many calling the plunge an "overreaction" and a buying opportunity given strong institutional ownership and pipeline potential. Others express frustration with management, viewing the guidance as conservative while anticipating future catalysts like the Kidney Care Access Protection Act and REZZAYO trial data.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is experiencing significant market attention following a new pre-production order for GPU-accelerated systems designed for U.S. Army combat vehicles, which is fueling community speculation about an impending, much larger defense contract. Investors are actively discussing the company's strong position in the AI and edge computing sectors, especially within the context of increasing defense spending, alongside its strengthened financial outlook after a recent asset sale. The low share float and perceived undervaluation are key talking points, driving heightened interest and trading volume.

Monero

Monero (XMR) is trending with strong momentum as its fundamental privacy features take center stage amidst growing market demand for anonymity. The community widely regards XMR as the definitive privacy coin, often contrasting its robust, untraceable nature with Bitcoin's transparency. This narrative fuels significant bullish sentiment, with many anticipating continued gains as a truly uncensorable asset in the evolving crypto landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twelve research firms that are presently covering the company...

Solid Biosciences (NASDAQ:SLDB) Shares Down 2.2% - Here's What Happened

Solid Biosciences (NASDAQ:SLDB) Trading Down 2.2% - Here's Why...

Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the firm...

Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB

Bollard Group LLC bought a new position in shares of Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought...

Geode Capital Management LLC Purchases 979,294 Shares of Solid Biosciences Inc. $SLDB

Geode Capital Management LLC raised its position in Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 184.5% in the second quarter, according to its most recent disclosure with the SEC. The firm...

Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CTO Paul Herzich sold 2,701 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average...

Jessie Hanrahan Sells 4,483 Shares of Solid Biosciences (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) insider Jessie Hanrahan sold 4,483 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an...

Solid Biosciences (NASDAQ:SLDB) CEO Sells 10,808 Shares

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CEO Alexander Cumbo sold 10,808 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an...

Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells 4,932 Shares of Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) COO David Howton sold 4,932 shares of the company's stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...

Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst

Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.read more...

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Solid Biosciences Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

The company received FDA Orphan Drug Designation for SGT-212, a key step in developing treatment for Friedreich's Ataxia, though initial clinical data is not expected until H2 2026.

Many traders are expressing disappointment over the stock's muted price reaction despite the positive FDA news, with some expecting a much larger surge.

Discussions focus on potential catalysts like an upcoming conference and ambitious price targets ranging from $6 to $20, viewing the company as a long-term biotech investment.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.50	--	--	N/A
Q3 '25	-$0.43	-$0.48	-10.90%	MISSED
Q2 '25	-$0.50	-$0.42	15.41%	BEAT
Q1 '25	-$0.56	-$0.59	-6.28%	MISSED
Q4 '24	-$0.80	-$1.00	-24.23%	MISSED

SLDB
Solid Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest SLDB News

SLDBSolid Biosciences Inc